TY - JOUR
T1 - The role of 5α-reductase type 1 associated with intratumoral dihydrotestosterone concentrations in human endometrial carcinoma
AU - Tanaka, Sota
AU - Miki, Yasuhiro
AU - Hashimoto, Chiaki
AU - Takagi, Kiyoshi
AU - Doe, Zhulanqiqige
AU - Li, Bin
AU - Yaegashi, Nobuo
AU - Suzuki, Takashi
AU - Ito, Kiyoshi
N1 - Publisher Copyright:
© 2014 Elsevier Ireland Ltd.
PY - 2015/2/5
Y1 - 2015/2/5
N2 - Endometrial carcinoma, especially endometrioid endometrial adenocarcinoma, is an estrogen-dependent tumor that is similar to breast cancer. Androgen is closely associated with other steroid hormones, but its correlation with endometrioid endometrial adenocarcinoma remains largely unclear. We previously demonstrated the expression of the androgen receptor, 5α-reductase type 1, and 5α-reductase type 2 in endometrioid endometrial adenocarcinoma tissue, but androgen action and its correlation with prognosis are unknown. In this study, we measured the tissue and serum concentrations of androgen and performed immunohistochemical analyses of androgen-associated factors in 41 patients. In 86 additional patients, we performed the same immunohistochemical analyses to identify correlations associated with prognosis. We found that 5α-reductase type 1 was associated with intratumoral dihydrotestosterone concentrations, and it was an independent prognostic factor in endometrioid endometrial adenocarcinoma. The poor prognosis of patients negative for both androgen receptor and 5α-reductase type 1 suggests that androgens have inhibitory effects on tumor growth.
AB - Endometrial carcinoma, especially endometrioid endometrial adenocarcinoma, is an estrogen-dependent tumor that is similar to breast cancer. Androgen is closely associated with other steroid hormones, but its correlation with endometrioid endometrial adenocarcinoma remains largely unclear. We previously demonstrated the expression of the androgen receptor, 5α-reductase type 1, and 5α-reductase type 2 in endometrioid endometrial adenocarcinoma tissue, but androgen action and its correlation with prognosis are unknown. In this study, we measured the tissue and serum concentrations of androgen and performed immunohistochemical analyses of androgen-associated factors in 41 patients. In 86 additional patients, we performed the same immunohistochemical analyses to identify correlations associated with prognosis. We found that 5α-reductase type 1 was associated with intratumoral dihydrotestosterone concentrations, and it was an independent prognostic factor in endometrioid endometrial adenocarcinoma. The poor prognosis of patients negative for both androgen receptor and 5α-reductase type 1 suggests that androgens have inhibitory effects on tumor growth.
KW - 5α-reductase 1
KW - Androgen receptor
KW - Dihydrotestosterone
KW - Endometrioid endometrial cancer
UR - http://www.scopus.com/inward/record.url?scp=84919934621&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84919934621&partnerID=8YFLogxK
U2 - 10.1016/j.mce.2014.11.022
DO - 10.1016/j.mce.2014.11.022
M3 - Article
C2 - 25475427
AN - SCOPUS:84919934621
VL - 401
SP - 56
EP - 64
JO - Molecular and Cellular Endocrinology
JF - Molecular and Cellular Endocrinology
SN - 0303-7207
ER -